Does infusion timing matter in TNBC? Early-day pembrolizumab may boost pCR and cut recurrences, prompting new scheduling questions.
Xianghui Zou
Advertisement
Articles by Xianghui Zou
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Capivasertib Combo Earns FDA Approval in PTEN-Deficient Metastatic HSPC
2
FDA Approves Adjuvant Belzutifan/Pembrolizumab in Clear Cell RCC Post Nephrectomy
3
Anbenitamab Regimen Meets Phase 3 End Points in HER2+ Breast Cancer
4
Tisa-Cel Yields Enduring Remissions in Younger High-Risk B-ALL Population
5